Copy Link Print Information

Birinapant

(Synonyms: TL32711)
44 Cited Publications
Revisión del cliente

Based on 44 publication(s) in Google Scholar

Birinapant (TL32711), a bivalent Smac mimetic, is a potent antagonist for XIAP and cIAP1 with Kds of 45 nM and less than 1 nM, respectively. Birinapant (TL32711) induces the autoubiquitylation and proteasomal degradation of cIAP1 and cIAP2 in intact cells, which results in formation of a RIPK1: caspase-8 complex, caspase-8 activation, and induction of tumor cell death. Birinapant (TL32711) targets TRAF2-associated cIAPs and abrogates TNF-induced NF-κB activation.

Para uso exclusivo en investigación. No vendemos a pacientes.

  • Pureza: 99.70%
  • No. CAS: 1260251-31-7
  • Fòrmula: C42H56F2N8O6
  • Peso molecular:806.94
  • Almacenamiento:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 6 months , -20°C, 1 month
  • Birinapant Chemical Structure
    Birinapant Chemical Structure
  • Experimental Validation Results for Birinapant
  • Experimental Validation Results for Birinapant
  • Experimental Validation Results for Birinapant
  • Experimental Validation Results for Birinapant
  • Experimental Validation Results for Birinapant
  • Experimental Validation Results for Birinapant
  • Experimental Validation Results for Birinapant
No. CAS: 1260251-31-7
Tamaño
Precio
Stock
Cantidad
Amount: USD 0.00
Please select quantity
or
or

* Seleccione Cantidad antes de agregar artículos.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Encuentre su distribuidor local Your local distributor: Hycultec GmbHHycultec
  • Actividad biológica
  • Chemical Information
  • Solvente y solubilidad
  • Pureza y Documentación
  • Referencias
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Birinapant

More
Customer Validation & Images
Cell Proliferation/Viability AssayIn Vivo Efficacy StudyFlow CytometryWB
  • Cell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • In Vivo Efficacy Study
  • Flow Cytometry
  • WB
  • WB
  • WB

Ver todos los productos específicos de isoformas IAP

More

Ver todos los productos específicos de isoformas HIV

More
Keywords
100 mg

Obtener un presupuesto En stock

Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Inicie sesiòn
Registrar
Sign in to MedChemExpress
Registrar una cuenta nueva

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Birinapant Chemical Structure
    Birinapant Chemical Structure
    1/16
  • 1/16

    Birinapant purchased from MedChemExpress. Usage Cited in: Cell. 2025 Jun 12;188(12):3219-3237.e18. [Abstract]

    Customer Validation
     Viability of shLuc+/Vec-, shCD36+/Vec-, shCD36+/CD36- HCC1806 cells determined by MTT assays after incubation with increasing concentrations of Birinapant.

  • 1/16

    Birinapant purchased from MedChemExpress. Usage Cited in: Cancer Res. 2023 Oct 2;83(19):3284-3304. [Abstract]

    Customer Validation
     Cell growth studies of MCF7 cells treated with vehicle (DMSO), fulvestrant, Birinapant (100 nmol/L), and the combination for 7 days. The number of cells were measured at days 0, 3, 5, and 7.

  • 1/16

    Birinapant purchased from MedChemExpress. Usage Cited in: Cancer Res. 2023 Oct 2;83(19):3284-3304. [Abstract]

    Customer Validation
     ER+/HER2- PDX tumor growth study. Mice received Birinapant (20 mg/kg I.P., 3d/week for 5 weeks).

  • 1/16

    Birinapant purchased from MedChemExpress. Usage Cited in: Cancer Res. 2023 Oct 2;83(19):3284-3304. [Abstract]

    Customer Validation
     Median fluorescence intensity (MFI) quantification of MHC-I and PD-L1 levels assessed by flow cytometry in MCF7 cells grown in HD or in the presence of E2. MCF7 cells were pretreated with vehicle, fulvestrant (10 nmol/L), Birinapant (100 nmol/L) and the combination of both drugs for 48 hours.

  • 1/16

    Birinapant purchased from MedChemExpress. Usage Cited in: Cancer Res. 2023 Oct 2;83(19):3284-3304. [Abstract]

    Customer Validation
     Whole-cell lysates immunoblots of ER, NF-KB subunits, and IFNg target genes in MCF7 cells grown treated with vehicle control (DMSO), Fulvestrant (10 nmol/L), Birinapant (100 nmol/L), and the combination with and without IFNg (10 ng/mL) stimulation for 24 hours.

  • 1/16

    Birinapant purchased from MedChemExpress. Usage Cited in: Cell. 2019 Jul 25;178(3):585-599.e15. [Abstract]

    Customer Validation
     Western blot analysis of polyclonal pools of sgCtrl or sgTRAF2-expressing SK-MEL-23 melanoma cells in the presence or absence of Birinapant, and upon coculture with MART-1 T cell for indicated amounts of time.

  • 1/16

    Birinapant purchased from MedChemExpress. Usage Cited in: Front Microbiol. 2018 Sep 19:9:2022. [Abstract]

    Customer Validation
     ACH-2 cells are exposed to Birinapant (50 nM) in the presence or absence of PEP005 (5 nM), with TNF-α (10 ng/ml) co-treatment for 24 h, and cell lysates are used for WB analysis.

  • Birinapant